1999 Legislation
Print Friendly

HOUSE BILL NO. 19 – Carisoprodol, controlled substance

HOUSE BILL NO. 19

View Daily Data Tracking History

View Bill Text

View Statement of Purpose / Fiscal Impact



Text to be added within a bill has been marked with Bold and
Underline. Text to be removed has been marked with
Strikethrough and Italic. How these codes are actually displayed will
vary based on the browser software you are using.

This sentence is marked with bold and underline to show added text.

This sentence is marked with strikethrough and italic, indicating
text to be removed.

Daily Data Tracking History



H0019........................................................by MR. SPEAKER
                      Requested by Board of Pharmacy
CONTROLLED SUBSTANCE ACT - Amends existing law to add carisoprodol to
Schedule IV of the Uniform Controlled Substance Act.

01/11    House intro - 1st rdg - to printing
01/11    Rpt prt - to Health/Wel

Bill Text


H0019

                                                                        
 ||||              LEGISLATURE OF THE STATE OF IDAHO             ||||
Fifty-fifth Legislature                 First Regular Session - 1999
                                                                        

                             IN THE HOUSE OF REPRESENTATIVES

                                    HOUSE BILL NO. 19

                                      BY MR. SPEAKER
                             Requested by: Board of Pharmacy

 1                                        AN ACT
 2    RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT; AMENDING  SECTION  37-2711,
 3        IDAHO  CODE,  BY THE ADDITION OF CARISOPRODOL TO CONTROLLED SUBSTANCES AND
 4        TO MAKE TECHNICAL CORRECTIONS.

 5    Be It Enacted by the Legislature of the State of Idaho:

 6        SECTION 1.  That Section 37-2711, Idaho Code, be, and the same  is  hereby
 7    amended to read as follows:

 8        37-2711.  SCHEDULE  IV.  (a)  Schedule  IV  shall consist of the drugs and
 9    other substances, by whatever official name, common or  usual  name,  chemical
10    name, or brand name designated, listed in this section.
11        (b)  Narcotic  drugs.  Unless  specifically  excepted  or unless listed in
12    another schedule, any material, compound, mixture, or  preparation  containing
13    any  of  the  following  narcotic drugs, or their salts calculated as the free
14    anhydrous base or alkaloid, in limited quantities as set forth below:
15        (1)  No more than 1 milligram of difenoxin and not less than 25 micrograms
16        of atropine sulfate per dosage unit;
17        (2)  Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
18        2-diphenyl-3-methyl-2-propionoxybutane).
19        (c)  Depressants. Unless specifically excepted or unless listed in another
20    schedule, any material, compound, mixture, or preparation which  contains  any
21    quantity  of the following substances, including its salts, isomers, and salts
22    of isomers whenever the existence of such salts, isomers, and salts of isomers
23    is possible within the specific chemical designation:
24        (1)  Alprazolam;
25        (2)  Barbital;
26        (3)  Bromazepam;
27        (4)  Camazepam;
28        (5)  Chloral betaine;
29        (6)  Chloral hydrate;
30        (7)  Chlordiazepoxide;
31        (8)  Clobazam;
32        (9)  Clonazepam;
33        (10) Clorazepate;
34        (11) Clotiazepam;
35        (12) Cloxazolam;
36        (13) Delorazepam;
37        (14) Diazepam;
38        (15) Estazolam;
39        (16) Ethchlorvynol;
40        (17) Ethinamate;
41        (18) Ethyl loflazepate;
42        (19) Fludiazepam;
43        (20) Flurazepam;


                                          2

 1        (21) Halazepam;
 2        (22) Haloxazolam;
 3        (23) Ketazolam;
 4        (24) Loprazolam;
 5        (25) Lorazepam;
 6        (26) Lormetazepam;
 7        (27) Mebutamate;
 8        (28) Medazepam;
 9        (29) Meprobamate;
10        (30) Methohexital;
11        (31) Methylphenobarbital (mephobarbital);
12        (32) Midazolam;
13        (33) Nimetazepam;
14        (34) Nitrazepam;
15        (35) Nordiazepam;
16        (36) Oxazepam;
17        (37) Oxazolam;
18        (38) Paraldehyde;
19        (39) Petrichloral;
20        (40) Phenobarbital;
21        (41) Pinazepam;
22        (42) Prazepam;
23        (43) Temazepam;
24        (44) Tetrazepam;
25        (45) Triazolam;
26        (46) Quazepam;
27        (47) Zolpidem.
28        (d)  Fenfluramine -- Any material, compound, mixture, or preparation which
29    contains any quantity  of  the  following  substances,  including  its  salts,
30    isomers  (whether optical, position, or geometric), and salts of such isomers,
31    whenever the existence of such salts, isomers, and salts of isomers is  possi-
32    ble:
33        (1)  Fenfluramine.
34        (e)  Stimulants.  Unless specifically excepted or unless listed in another
35    schedule, any material, compound, mixture, or preparation which  contains  any
36    quantity  of the following substances having a stimulant effect on the central
37    nervous system, including its salts, isomers (whether  optical,  position,  or
38    geometric),  and  salts  of such isomers whenever the existence of such salts,
39    isomers, and salts of isomers is possible within the specific chemical  desig-
40    nation:
41        (1)  Cathine ((+)-norpseudoephedrine);
42        (2)  Diethylpropion;
43        (3)  Fencamfamin;
44        (4)  Fenproporex;
45        (5)  Mazindol;
46        (6)  Mefenorex;
47        (7)  Pemoline (including organometallic complexes and chelates thereof);
48        (8)  Phentermine;
49        (9)  Pipradrol;
50        (10) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
51        (f)  Other  substances.  Unless specifically excepted, or unless listed in
52    another schedule, any material, compound, mixture or  preparation  which  con-
53    tains  any  quantity of the following substance s , including 
54    its   their  salts:
55        (1)  Pentazocine ; 


                                          3

 1         (2)  Carisoprodol .
 2        (g)  The board may except by rule any compound,  mixture,  or  preparation
 3    containing  any  depressant substance listed in subsection (c) of this section
 4    from the application of all or any part of this act if the compound,  mixture,
 5    or preparation contains one  (1)  or more active medicinal ingredi-
 6    ents  not having a depressant effect on the central nervous system, and if the
 7    admixtures are included therein in combinations, quantity, proportion, or con-
 8    centration that vitiate the potential for abuse of the substances which have a
 9    depressant effect on the central nervous system.

Statement of Purpose / Fiscal Impact


                      STATEMENT  OF  PURPOSE
                             RS08347
Add to Idaho Code 37-2711 Schedule IV of the Uniform Controlled
Substance Act Chapter 27, Title 37, the drug carisoprodol.  This
change is being requested because of the increased abuse of this
drug.  Restricts prescriptions for this drug to five refills or six
months and will place it in the tracking system.




                         FISCAL  IMPACT
No impact on the General Fund.  No cost to the general public or
practitioners.  Implementation of legislation will be from the
Board of Pharmacy dedicated funds.





CONTACT   
Name:     Richard Markuson
Agency:   Board of Pharmacy
Phone:    334-2356

Statement of Purpose/Fiscal Impact                             H 1